AC Immune amends Lilly collaboration for tau drug development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
April 7, 2026 7:00 AM EDTAC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer small moleculesInvestigational New Drug (IND)-enabling studies to commence in H1 2026Lausanne, Switzerland, April 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced an agreement with Eli Lilly and Company (Lilly) to amend their 2018... More
